Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
843.60
+5.40 (+0.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
July 18, 2024
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth.
Via
Benzinga
3 Standout Stocks to Buy for the Next Bull Market
July 18, 2024
These standout stocks to buy for a bull market offer promising potential for significant gains as market conditions continue to strengthen.
Via
InvestorPlace
Stocks to Buy: 7 Founder-Led Companies Set to Outperform
July 17, 2024
These founder-led companies are at the forefront of industry innovation, and historical trends indicate that they will likely outperform.
Via
InvestorPlace
CPI Data Sparks Rally in Biotech Stocks
July 15, 2024
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
July 11, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
July 04, 2024
Via
Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
July 02, 2024
Via
Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
July 27, 2024
These companies are no strangers to beating the market.
Via
The Motley Fool
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
July 25, 2024
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.
Via
Benzinga
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
July 23, 2024
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six...
Via
Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
July 22, 2024
Via
Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
July 19, 2024
Via
Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
July 16, 2024
Via
Benzinga
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
July 15, 2024
Via
Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
July 15, 2024
Revenue is climbing at these two drug companies -- and the trend should continue.
Via
The Motley Fool
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
July 09, 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.
Via
InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
July 08, 2024
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.
Via
Talk Markets
3 No-Brainer Stocks to Buy in July
July 08, 2024
Investors shouldn't have to think too hard about these great stocks.
Via
The Motley Fool
3 Pharma Stocks Already Ushering in the Next Biotech Boom
July 08, 2024
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
Via
InvestorPlace
The 3 Best Biotech Stocks to Buy in July 2024
July 05, 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.
Via
InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
7 High Priced Stocks That Would Benefit From a Stock Split
July 04, 2024
These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names.
Via
InvestorPlace
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
July 03, 2024
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a...
Via
Benzinga
Exposures
Product Safety
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
June 28, 2024
Regeneron Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval of odronextamab. Final decision...
Via
Benzinga
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
June 28, 2024
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell...
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
June 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
June 27, 2024
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.
Via
Benzinga
Exposures
Product Safety
3 Biotech Stocks That Could Make Your Grandchildren Rich
June 27, 2024
These biotech stocks are poised to generate significant returns to investors due to their high growth potential.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.